Crohn's disease: beyond antagonists of tumour necrosis factor (original) (raw)

Tumor Necrosis Factor’s Pathway in Crohn’s Disease: Potential for Intervention

Fabio Cominelli

International Journal of Molecular Sciences, 2021

View PDFchevron_right

Update on anti-tumor necrosis factor agents in Crohn disease

Siddharth Singh

Gastroenterology clinics of North America, 2014

View PDFchevron_right

AntiTumor Necrosis Factor-Alpha (TNF-α) Treatment Strategies in Crohn's Disease

Christian D Muller

Recent Patents on Inflammation & Allergy Drug Discovery, 2007

View PDFchevron_right

Crohn's disease: future anti–tumor necrosis factor therapies beyond infliximab

Joshua Korzenik

Gastroenterology Clinics of North America, 2004

View PDFchevron_right

Optimizing the Use of Tumour Necrosis Factor Inhibitors in Crohnʼs Disease

Maria Etchevers

Drugs, 2010

View PDFchevron_right

Crohn’s Disease Biologic Therapies Advances: A current review

Jorge Balteiro

2017

View PDFchevron_right

Anti-Tumor Necrosis Factor-Alpha (TNF-α) Treatment Strategies in Crohns Disease

Brigitte Sola

Recent Patents on Inflammation & Allergy Drug Discovery, 2007

View PDFchevron_right

Review article: biological agents in the treatment of Crohn's disease

Angelo Viscido

Alimentary Pharmacology & Therapeutics

View PDFchevron_right

Recommendations for the treatment of Crohnʼs disease with tumor necrosis factor antagonists: An expert consensus report

Dario Sorrentino

Inflammatory Bowel Diseases, 2012

View PDFchevron_right

Novel strategies to attenuate immune activation in Crohn's disease

Giorgos Bamias

Current Opinion in Pharmacology, 2006

View PDFchevron_right

Biological agents in the treatment of Crohn's disease

Angelo Viscido

Alimentary Pharmacology and Therapeutics, 2002

View PDFchevron_right

An engineered human antibody to TNF (CDP571) for active Crohn's disease: a randomized double-blind placebo-controlled trial

William Sandborn

Gastroenterology, 2001

View PDFchevron_right

Role of the tumor necrosis factor antagonists in the treatment of inflammatory bowel disease: an update

Lorenzo Leggio

European Journal of Gastroenterology & Hepatology, 2010

View PDFchevron_right

Infliximab induces potent anti-inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn's disease

J. Ceuppens, K. Geboes

Alimentary Pharmacology and Therapeutics, 2001

View PDFchevron_right

Potential therapeutic role for cytokine or adhesion molecule manipulation in Crohn's disease: in the shadow of infliximab?

Alastair Forbes

International Journal of Colorectal Disease, 2003

View PDFchevron_right

Anti-tumor necrosis factor treatment restores the gut barrier in Crohn's disease

Benny Geypens

The American journal …, 2002

View PDFchevron_right

CDP571, a Humanized Anti-Tumor Necrosis Factor-α Monoclonal Antibody in Pediatric Crohn’s Disease

Jatin Patel

Inflammatory Bowel Diseases, 2004

View PDFchevron_right

Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety

William Sandborn

Inflammatory bowel diseases, 1999

View PDFchevron_right

Novel therapies for Crohn’s disease

Ioannis Koutroubakis

View PDFchevron_right

Biological Therapy in the Prevention of Complications of Crohn

Dolores Ortiz

Biological Therapy for Inflammatory Bowel Disease, 2020

View PDFchevron_right

Do anti-tumor necrosis factors induce response and remission in patients with acute refractory Crohn's disease? A systematic meta-analysis of controlled clinical trials

Shekoufeh Nikfar

Biomedecine & Pharmacotherapy, 2007

View PDFchevron_right

Inflammatory Cytokine Profile in Crohn's Disease Nonresponders to Optimal Antitumor Necrosis Factor Therapy

Anjali Jain

Journal of clinical gastroenterology, 2018

View PDFchevron_right

A randomized, double‐blind, placebo‐controlled trial of CDP571, a humanized monoclonal antibody to tumour necrosis factor‐α, in patients with corticosteroid‐dependent Crohn's disease

Bruce Salzberg MD, FACG

Alimentary Pharmacology & Therapeutics, 2005

View PDFchevron_right

Biologics in inflammatory bowel disease: how much progress have we made?

William Sandborn

Gut, 2004

View PDFchevron_right

Biologic therapies in inflammatory bowel disease

Manuela Neuman

Translational Research, 2014

View PDFchevron_right

A critical approach to new forms of treatment of Crohn's disease and ulcerative colitis

Amado Salvador Peña

Alimentary Pharmacology & Therapeutics, 2002

View PDFchevron_right

The Influence of Innate and Adaptive Immunity on Crohn’s Disease Severity

Keith Sacco

Journal of Clinical & Cellular Immunology, 2014

View PDFchevron_right

Inhibitors of Tumoral Necrosis Factor Alpha in Inflammatory Bowel Disease

Carlos Walter Sobrado

Biological Therapy for Inflammatory Bowel Disease, 2020

View PDFchevron_right

Loss of Response to Anti-Tumor Necrosis Factor Alpha Therapy in Crohn's Disease Is Not Associated with Emergence of Novel Inflammatory Pathways

Suraj Patel

Digestive diseases and sciences, 2018

View PDFchevron_right

Real world analysis on the efficacy and safety of anti-tumor necrosis factor therapy in patients with stricturing Crohn’s disease

Govind Makharia

Scientific Reports, 2021

View PDFchevron_right

Inflammatory Bowel Disease: An Overview of Immune Mechanisms and Biological Treatments

Bruno de Mattos

Mediators of Inflammation, 2015

View PDFchevron_right

Preclinical Development of a Novel, Orally-Administered Anti-Tumour Necrosis Factor Domain Antibody for the Treatment of Inflammatory Bowel Disease

Luis Miguel Mendoza

Scientific reports, 2018

View PDFchevron_right

Clinical profiles of moderate and severe Crohn's disease patients and use of anti-tumor necrosis factor agents: Greek expert consensus guidelines

Gerassimos Mantzaris

Annals of gastroenterology : quarterly publication of the Hellenic Society of Gastroenterology

View PDFchevron_right

Review Article Inflammatory Bowel Disease: An Overview of Immune Mechanisms and Biological Treatments

Bruno de Mattos

Mediators of Inflammation

View PDFchevron_right

Infliximab induced T lymphocyte apoptosis in Crohn's disease

Maikel Peppelenbosch

The Journal of rheumatology. Supplement, 2005

View PDFchevron_right